Patent intelligence · US
US 8697633
Dissolution of arterial plaque
Dissolution of arterial plaque
Patent details — US 8697633
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 15, 2014
- Expiration
- Apr 10, 2034
- Applicant
- Atheronova Operations, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/56, A61K9/0019, A61K9/7023
Quick answer
US 8697633 (Dissolution of arterial plaque) is held by Atheronova Operations, Inc.. Status: granted. Granted Apr 15, 2014. Expires Apr 10, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atheronova Operations, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/56, A61K9/0019, A61K9/7023, A61P, A61P9/10
More from Atheronova Operations, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 8697633?
US 8697633 (Dissolution of arterial plaque) is held by Atheronova Operations, Inc.. Status: granted. Granted Apr 15, 2014. Expires Apr 10, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8697633?
Atheronova Operations, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 8697633 expire?
Our index shows an expiration date of Apr 10, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.